Harnessing Decentralized Clinical Trials to Improve Access in Rare Disease Research

The Rationale for Decentralization in Rare Disease Trials

Rare disease trials face one central challenge: patient scarcity scattered across vast geographies. Traditional site-based clinical trials often fail to recruit sufficient participants due to travel limitations, disease burden, or lack of specialized centers near patients. Decentralized Clinical Trials (DCTs)—which integrate remote, digital, and home-based trial components—offer a transformative solution.

DCTs eliminate the need for patients to live near or travel frequently to clinical sites. This is particularly advantageous in ultra-rare conditions, where eligible patients may be located across countries or continents. By shifting clinical activities to the patient’s home or local setting, DCTs increase participation feasibility, reduce patient burden, and support patient-centric research designs.

Regulatory agencies, including the FDA and EMA, have embraced DCTs, especially during the COVID-19 pandemic. They have since issued guidance to support the continued use of decentralized models where appropriate—especially in rare disease research where accessibility is a critical factor in trial success.

Core Components of a Decentralized Rare Disease Trial

A well-designed decentralized trial for a rare disease may include a blend of virtual and on-site elements to maximize flexibility while ensuring data integrity. Common DCT components include:

• Telemedicine Visits: Virtual clinical consultations for enrollment, follow-up, or AE monitoring
• eConsent Platforms: Digital informed consent tools with multilingual or pediatric customization
• Direct-to-Patient Shipment: Delivery of study drugs or kits to patient homes
• Wearable Devices: Continuous monitoring of physiological endpoints (e.g., motor activity, sleep patterns)
• Mobile Healthcare Providers: Nurses conducting in-home sample collection or assessments

These components allow sponsors to conduct research with a minimal geographic footprint while maintaining regulatory compliance and data quality.

Continue Reading: Regulatory Challenges, Real-World DCT Implementation, and Case Study Insights

Regulatory Considerations for DCTs in Rare Disease Trials

While DCTs offer significant advantages, their adoption in rare disease studies must align with regulatory expectations. The FDA’s 2023 Draft Guidance on DCTs outlines key areas of focus, such as remote data verification, informed consent documentation, and the use of digital health technologies.

EMA similarly supports decentralized models but emphasizes data protection, the need for contingency planning in case of remote failure, and consistency of medical assessments across settings. Sponsors should anticipate and address these concerns during early regulatory interactions.

• Risk-Based Monitoring: Implement centralized monitoring supported by remote data analytics
• GCP Compliance: Ensure all digital tools meet 21 CFR Part 11 or EU Annex 11 requirements
• Data Privacy: Align with GDPR and HIPAA where applicable

Early engagement with agencies through pre-IND meetings or EMA’s Innovation Task Force can help sponsors clarify DCT feasibility and protocol design before launch.

Case Study: DCT in a Pediatric Ultra-Rare Disorder

A biotech company initiated a Phase II trial for a pediatric neurodegenerative disorder (affecting fewer than 300 children globally). Traditional site-based enrollment failed due to geographic constraints and disease progression. The study was redesigned as a decentralized trial with the following components:

• Video-based neurological assessments using standardized rating scales
• Home nursing visits for blood draws and physical therapy guidance
• Parent-reported ePROs using a mobile application
• Central pharmacy distribution of investigational product with video instructions

Over 90% of eligible patients enrolled within three months. Adherence improved, and no data quality issues were raised during the FDA Type B meeting. The trial demonstrated that rare disease studies can succeed with decentralized architecture.

Opportunities: Broader Inclusion and Better Engagement

DCTs unlock new possibilities in rare disease research. Patients who were previously excluded due to mobility issues, distance, or caregiver constraints can now be included, increasing trial diversity and accelerating enrollment timelines.

• Cross-Border Enrollment: Multinational patient inclusion without added travel burden
• Improved Retention: Reduction in patient fatigue and site visit dropout
• Pediatric Flexibility: Caregiver involvement through digital diaries and video support
• Real-World Data Collection: Wearables and sensors enable continuous assessment of quality-of-life parameters

For rare disease trials with subjective or longitudinal endpoints (e.g., fatigue, sleep, developmental milestones), these technologies capture more frequent and ecologically valid data points than intermittent clinic visits.

Risks and Challenges of DCT Implementation

Despite their advantages, DCTs present several operational and methodological risks:

• Data Heterogeneity: Inconsistent data quality across sites, devices, or countries
• Tech Literacy Barriers: Not all patients or caregivers are comfortable with digital platforms
• Device Calibration: Wearables may need validation for rare disease-specific measurements
• Connectivity Issues: Internet limitations in rural or resource-limited settings
• Site Coordination: Local investigator oversight still required for GCP compliance

Mitigation strategies include hybrid trial models, extensive patient training, cloud-based audit trails, and backup site infrastructure where necessary. Importantly, patient advocacy groups can provide feedback on proposed technologies during protocol development.

Tools and Platforms Supporting Decentralization

Many sponsors partner with technology providers to implement DCT elements. Examples of tools include:

• eConsent & ePRO Platforms: Medidata, Signant Health, Castor
• Telehealth Systems: VSee, Doxy.me integrated with EDC systems
• Wearables: ActiGraph, Apple Watch, Withings for heart rate, gait, and sleep
• Remote Labs & Logistics: Marken, LabCorp Mobile, IQVIA’s home visit network

Successful implementation requires cross-functional coordination between sponsors, CROs, tech vendors, and clinical sites. Additionally, patients must be involved in early usability testing of DCT tools.

Future Outlook: Mainstreaming DCTs in Rare Trials

As regulatory clarity improves and digital technology advances, decentralized trials are expected to become standard in rare disease development. The next phase will involve:

• Validation of remote endpoints
• Development of decentralized trial-specific GCP frameworks
• Wider access to global teletrial networks
• Blockchain-based patient ID verification and data tracking

Global registries like Be Part of Research (NIHR) are increasingly integrating DCT-ready patient identification and e-consent features for rare disease recruitment, streamlining the research pathway.

Conclusion: Bridging the Gap with DCTs in Rare Disease Trials

Decentralized clinical trials present a powerful model to address the core challenges of rare disease research—geographic dispersion, low patient numbers, and heavy clinical burden. By adopting flexible, patient-centric strategies and aligning with evolving regulatory standards, sponsors can unlock access to previously unreachable populations.

Though challenges remain, the benefits of DCTs—especially for rare and pediatric disorders—outweigh the limitations when implemented thoughtfully. The future of rare disease trials lies not in more sites, but in more connection—powered by innovation, compassion, and decentralization.

Strategies to Minimize Travel Burden in Rare Disease Clinical Trials

Why Travel Is a Barrier in Rare Disease Research

In rare disease clinical trials, eligible patients often reside far from trial sites, which are typically concentrated in major cities or academic centers. Given the small and globally dispersed patient populations, it’s not uncommon for participants to travel hundreds or even thousands of kilometers to access a site. This travel burden can discourage enrollment, increase dropout risk, and disproportionately exclude rural or low-income participants.

Moreover, many rare disease patients are children, elderly, or have mobility challenges that make long-distance travel physically, emotionally, and financially taxing. Recognizing and addressing this barrier is essential to achieving equitable and successful clinical trial participation.

Key Travel-Related Challenges in Rare Disease Trials

Participants and their caregivers may encounter several obstacles related to travel, including:

• Geographic Isolation: Trial sites may be located in only a handful of countries, requiring international travel for some participants.
• Financial Constraints: Costs associated with airfare, lodging, meals, and local transport can be prohibitive, especially for multi-visit studies.
• Medical Fragility: Many patients are immunocompromised, wheelchair-bound, or dependent on caregivers, making travel risky and complex.
• Visa and Documentation Delays: Cross-border travel introduces administrative delays that can exclude otherwise eligible patients.

Left unaddressed, these burdens compromise both trial diversity and scientific integrity.

Implementing Site-to-Patient (S2P) Trial Models

One of the most effective ways to reduce travel burden is through decentralized or hybrid trial models that bring the study to the patient. Components of S2P models include:

• Home Health Visits: Trained nurses conduct assessments, sample collection, and safety checks at the patient’s home.
• Telemedicine Visits: Video-based investigator check-ins reduce the need for in-person site visits.
• Mobile Sites: Use of vans or portable equipment for conducting local procedures in rural settings.
• Local Lab Partnerships: Leveraging nearby diagnostics facilities for routine tests and sample shipments.

These approaches can be implemented selectively based on study phase, complexity, and patient condition.

Travel Logistics and Reimbursement Programs

When travel is unavoidable, sponsors must provide comprehensive support to ensure participants can attend without financial strain. Best practices include:

• Centralized Travel Coordination: Provide patients with a dedicated travel concierge to manage booking, itineraries, and special needs (e.g., wheelchair-accessible transport).
• Advance Reimbursement: Offer pre-paid travel cards or upfront disbursements to avoid out-of-pocket expenses.
• Lodging Support: Partner with hotels near sites that accommodate patient-specific needs.
• Caregiver Stipends: Include caregiver travel costs and per diems as part of trial budgeting.

These services reduce dropout due to travel stress and demonstrate respect for patient time and resources.

Case Study: Multi-Country Trial Using Decentralized Visits

In a global rare epilepsy trial, the sponsor implemented decentralized visits for long-term follow-up. Patients in Canada, Brazil, and Eastern Europe were offered the choice between on-site and home-based visits.

Outcomes included:

• 35% of participants opted for hybrid participation (some on-site, some remote)
• Travel-related withdrawal dropped by 60% from previous trials
• Enrollment increased in rural provinces with previously zero participation

This example shows that travel flexibility leads to more diverse and engaged trial populations.

Leveraging Local Partnerships for Patient Support

Partnering with community healthcare providers, rare disease clinics, and patient organizations can help reduce the need for long-distance travel. These partners can:

• Perform routine procedures closer to the patient’s home
• Assist with medication delivery or IV administration
• Offer emotional and logistical support to caregivers
• Act as trusted liaisons between patients and trial teams

Engaging local resources can expand trial reach and reduce the site burden simultaneously.

Technology Solutions to Support Remote Participation

Digital tools help bridge the gap between sites and remote participants:

• ePRO Apps: Allow patients to submit data without site visits.
• Telehealth Platforms: Enable secure, compliant video assessments with investigators.
• Remote Monitoring Devices: Wearables collect real-time data on vitals, movement, or sleep patterns.
• Virtual Site Portals: Provide access to visit schedules, trial education materials, and direct communication with coordinators.

These tools empower patients and reduce physical demands while maintaining data quality and compliance.

Regulatory Considerations and Risk Mitigation

Reducing travel burden must be balanced with regulatory compliance and patient safety. Sponsors should:

• Submit protocol amendments when shifting to remote models
• Ensure local IRBs approve travel support and reimbursement programs
• Use Good Clinical Practice (GCP)-trained home health providers
• Maintain documentation of decentralized procedures for audits

Proper documentation and oversight are essential to ensure decentralization enhances rather than compromises trial quality.

Conclusion: Reducing Burden, Increasing Access

Travel should never be the reason a patient misses the opportunity to participate in a potentially life-changing clinical trial—especially in the rare disease space where every participant matters. Sponsors and CROs must proactively design travel-inclusive and travel-flexible studies that empower, not exclude, patients.

By reducing physical and financial burdens, engaging local partners, and embracing decentralized tools, the rare disease community can move toward more equitable, accessible, and patient-centered clinical research.